Craig Erker
A5031468557- Glioma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Neurofibromatosis and Schwannoma Cases
- Childhood Cancer Survivors' Quality of Life
- Meningioma and schwannoma management
- Chromatin Remodeling and Cancer
- Cancer, Hypoxia, and Metabolism
- Brain Metastases and Treatment
- Sarcoma Diagnosis and Treatment
- Renal and related cancers
- Traumatic Brain Injury and Neurovascular Disturbances
- Melanoma and MAPK Pathways
- Lymphoma Diagnosis and Treatment
- Family Support in Illness
- Radiomics and Machine Learning in Medical Imaging
- Blood Coagulation and Thrombosis Mechanisms
- Palliative Care and End-of-Life Issues
- Venous Thromboembolism Diagnosis and Management
- Reproductive Biology and Fertility
- Spinal Fractures and Fixation Techniques
- Infectious Diseases and Mycology
- Histiocytic Disorders and Treatments
- CNS Lymphoma Diagnosis and Treatment
- Atomic and Subatomic Physics Research
- Radiation Therapy and Dosimetry
Izaak Walton Killam Health Centre
2019-2025
Dalhousie University
2019-2025
IWK Foundation
2021-2022
Halifax Health Medical Center
2022
Cincinnati Children's Hospital Medical Center
2018
Pediatrics and Genetics
2017
Medical College of Wisconsin
2015-2016
Wolfson Children's Hospital
2014
University of Saskatchewan
2013
Abstract Background Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in children. Up to 50% will be refractory conventional chemotherapy. It is now known that majority of PLGG have activation MAPK/ERK pathway. The same pathway also activated plexiform neurofibromas (PNs) which involving peripheral nerves patients with neurofibromatosis type 1 (NF1). These lesions Specific MEK inhibitors such as trametinib available and been approved for other cancers harboring mutations...
Background: Clinical trials of anti-Aβ monoclonal antibodies in Alzheimer disease (AD) infer target engagement from Aβ positron emission tomography (PET) and/or fluid biomarkers such as cerebrospinal (CSF) Aβ42/40.However, these measure deposits indirectly incompletely.In contrast, postmortem neuropathologic assessments allow direct investigation treatment effects on brain and many other pathologic features.Methods: From a clinical trial dominantly inherited AD, we measured...
Abstract Little is known about the impact of cancer on family relationships from perspective pediatric patient and their sibling(s). This study assessed compared children's experiences in patients receiving active therapy, those who have completed siblings. A cross‐sectional children with siblings aged 8–17 years old was conducted. Children PROMIS Pediatric Family Relationships short form Depressive Symptoms, Anxiety, Peer forms. The Mann–Whitney test differences scores between therapy...
A comprehensive review and description of the clinical features that impact prognosis for patients with diffuse hemispheric glioma, H3 G34-mutant (G34-DHG) is needed. Understanding survival prognostic paramount advancements patient care.
<div>AbstractPurpose:<p>Tropomyosin receptor kinase (TRK) fusions are detected in less than 2% of central nervous system tumors. There limited data on the clinical course affected patients.</p>Experimental Design:<p>We conducted an international retrospective cohort study patients with TRK fusion–driven tumors.</p>Results:<p>A total 119 were identified. The median age at time diagnosis was 4.5 years. majority reported to have a histology consistent...
<p>Supplementary Figure S1. Diagram of population patients.</p>
<p>Supplementary Figure S2. A) Hazard ratio for progression or death according to clinical characteristics. B) LGG: Low-grade glioma, HGG: High-grade glioma</p>
<p>Supplementary Data S1. Definition of response, Description response criteria used by sites to evaluate tumor extend resection, resection sites.</p>
Primary CNS tumors are the leading cause of cancer-related death in pediatrics. It is essential to understand treatment trends interpret national survival data. In Canada, children with treated at one 16 tertiary care centers. We surveyed pediatric neuro-oncologists create a standard practice be used absence clinical trial for seven most prevalent brain children. This allowed description across country, along consensus. had multitude benefits, including understanding patterns, allowing basis...
Diffuse intrinsic pontine gliomas (DIPG) generally occur in young school-age children, although can adolescents and adults. The purpose of this study was to describe clinical, radiological, pathologic, molecular characteristics patients ≥10 years age with DIPG enrolled the International Registry (IDIPGR).Patients at diagnosis IDIPGR imaging confirmed were included. primary outcome overall survival (OS) categorized as long-term survivors (LTS) (≥24 months) or short-term (STS) (<24...
2042 Background: Pediatric low-grade gliomas (PLGG) are the most frequent brain tumors in children and majority of PLGG have activation MAPK/ERK pathway. Plexiform neurofibromas (PN) found up to 50% patients with neurofibromatosis type 1 (NF1). Trametinib has been used widely treat PN, but no clinical trial reported its efficacy. Methods: This multicenter phase II includes aged ≥ month ≤ 25 years progressing/refractory groups or PN. The primary objective was evaluate overall response rate...
Infant and young childhood medulloblastoma (iMB) is usually treated without craniospinal irradiation (CSI) to avoid neurocognitive late effects. Unfortunately, many children relapse. The purpose of this study was assess salvage strategies prognostic features patients with iMB who relapse after CSI-sparing therapy.
The treatment of BRAF V600E gliomas with inhibitors (BRAFis) and MEK (MEKis) has been increasingly integrated into clinical practice for pediatric low-grade (PLGGs) high-grade (HGGs). However, some questions remain unanswered, such as the best time to start targeted therapy, duration treatment, discontinuation therapy. Given that no trial able address these critical questions, we developed a Canadian Consensus statement mutated well adolescent young adult (AYA) gliomas.